Benzinga · Oct 20, 2026
Why Is Actinium Pharmaceuticals Stock Gaining Tuesday?
Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.
AMEX · ATNM
Actinium Pharmaceuticals, Inc.
Healthcare · Biotechnology
$1.40
Down-$0.12 (-7.89%)
Updated Oct 27, 2026, 8:26 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 45.55M
- P/E ratio
- -1.32
- Dividend yield
- 0.00%
- 52-week range
- $0.74 – $1.74
- Volume
- 205.86K
- Avg. volume
- 205.89K
Price performance · ATNM
ATNM price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
ATNM closed at $1.40 after 21 trading sessions, up 18.64% for the selected period.
- Last close
- $1.40
- Period change
- +18.64%
- Period low
- $0.97
- Period high
- $1.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $1.50 | $1.53 | $1.36 | $1.40 | 205.86K |
| Oct 23, 2026 | $1.60 | $1.63 | $1.469 | $1.52 | 242.01K |
| Oct 22, 2026 | $1.33 | $1.66 | $1.33 | $1.60 | 828.82K |
| Oct 21, 2026 | $1.38 | $1.4087 | $1.33 | $1.38 | 358.23K |
| Oct 20, 2026 | $1.36 | $1.50 | $1.3501 | $1.40 | 901.05K |
| Oct 19, 2026 | $1.14 | $1.40 | $1.13 | $1.32 | 658.4K |
| Oct 16, 2026 | $1.09 | $1.15 | $1.05 | $1.13 | 174.39K |
| Oct 15, 2026 | $0.95 | $1.07 | $0.95 | $1.06 | 143.24K |
| Oct 14, 2026 | $0.99 | $1.0225 | $0.9518 | $0.9746 | 84.64K |
| Oct 13, 2026 | $1.07 | $1.07 | $0.9955 | $0.9995 | 89.25K |
| Oct 12, 2026 | $1.09 | $1.09 | $1.0292 | $1.06 | 98.46K |
| Oct 9, 2026 | $1.09 | $1.12 | $1.07 | $1.10 | 105.76K |
| Oct 8, 2026 | $1.09 | $1.10 | $1.06 | $1.08 | 104.87K |
| Oct 7, 2026 | $1.08 | $1.12 | $1.05 | $1.07 | 100.09K |
| Oct 6, 2026 | $1.20 | $1.22 | $1.02 | $1.11 | 439.58K |
| Oct 5, 2026 | $1.16 | $1.24 | $1.16 | $1.20 | 115.03K |
| Oct 2, 2026 | $1.15 | $1.19 | $1.12 | $1.17 | 81.8K |
| Oct 1, 2026 | $1.11 | $1.15 | $1.11 | $1.15 | 90.83K |
| Sep 30, 2026 | $1.14 | $1.20 | $1.10 | $1.12 | 95.13K |
| Sep 29, 2026 | $1.17 | $1.17 | $1.14 | $1.14 | 62.02K |
| Sep 28, 2026 | $1.18 | $1.20 | $1.17 | $1.18 | 75.37K |
Latest ATNM news
The latest Smart Investors Daily articles mentioning ATNM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ATNM research
Overview
Company profile and research snapshot.
Company profile
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $11.07
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 31, 2026 | Stephens & Co. | Overweight | — |
| Jun 24, 2025 | HC Wainwright & Co. | Buy | — |
| May 12, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 28, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 20, 2026
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced encouraging initial clinical results from the first‑in‑human Phase 1 study of ATNM‑400 in metastatic castration‑resistant prostate cancer (mCRPC). The findings, presented in an oral presentation on October 19 at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna,
Yahoo · Oct 20, 2026
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical results demonstrating the broad antitumor potential of ATNM-400 across non-small cell lung cancer (NSCLC), colorectal cancer and ovarian cancer models. The findings were presented in an oral presentation and two e-posters at the 39th Annual Congress of the European Association of Nucle
Benzinga · Oct 20, 2026
Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical results
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
